Treatment modalities to manage hepatocellular carcinoma patients with portal vein thrombosis: a systematic review and meta-analysis
Annals of Palliative Medicine · 2023
DOI: 10.21037/apm-23-463 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Annals of Palliative Medicine, 2023. Verfasst von Brandon Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: London Health Sciences Centre, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Venous Thrombosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND: A number of therapeutic treatment strategies exist for patients with hepatocellular carcinoma (HCC) and portal vein thrombosis (PVT). The aim of this review is to provide a current understanding of treatment options and determine the relative effectiveness of treatment options in preventing mortality over 24 months. METHODS: A search was conducted in PubMed, EMBASE and Cochrane CENTRAL from 2007 to 2022. Articles were screened to identify those that reported on all-cause mortality among treated, non-palliative patients with HCC and PVT. Study quality was assessed using the Cochrane Risk of Bias in Non-Randomized Studies of Interventions tool (ROBINS-1). Mortality rates at prespecified timepoints between 6 and 24 months were extracted and summarized using a random-effects DerSimonian-Laird model. This review was registered a priori on PROSPERO (CRD42022290708). RESULTS: When comparing radiotherapy (RT) to sorafenib and combined transarterial chemoembolization (TACE), there was a trend that RT yields better survival at 6 months [odds ratio (OR) 0.70, 95% confidence interval (CI): 0.28-1.76]. When comparing sorafenib to Y90 and RT, sorafenib was associated with higher odds for mortality at 6 months (OR 2.20, 95% CI: 1.11-4.39). No significant differences were noticed from 12 to 24 months. CONCLUSIONS: Future strategies for HCC with PVT should look at the combination of radiation and systemic treatments either concurrently or sequentially.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- London Health Sciences Centre, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada.
- Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.
- Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
- Brigham and Women's Hospital, Harvard Medical School, Harvard University, Boston, MA, USA.
- New York Proton Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- London Health Sciences Centre, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada; Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; New York Proton Center,…
Zitieren
APA
Liu, B., Grindrod, N., Meyers, B. M., Freiburger, S., Boldt, G., Malik, A., Jairam, M. P., Brahmania, M., Cardarelli Leite, L., Simone, C. B., Chow, R., & Lock, M. (2023). Treatment modalities to manage hepatocellular carcinoma patients with portal vein thrombosis: a systematic review and meta-analysis. Annals of Palliative Medicine. https://doi.org/10.21037/apm-23-463
Vancouver
Liu B, Grindrod N, Meyers BM, Freiburger S, Boldt G, Malik A, et al. Treatment modalities to manage hepatocellular carcinoma patients with portal vein thrombosis: a systematic review and meta-analysis. Annals of Palliative Medicine. 2023. doi:10.21037/apm-23-463
BibTeX
@article{Liu2023,
author = {Liu, Brandon and Grindrod, Natalie and Meyers, Brandon M and Freiburger, Sarah and Boldt, Gabriel and Malik, Aleena and Jairam, Meghan P and Brahmania, Mayur and Cardarelli Leite, Leandro and Simone, Charles B and Chow, Ronald and Lock, Michael},
title = {Treatment modalities to manage hepatocellular carcinoma patients with portal vein thrombosis: a systematic review and meta-analysis},
journal = {Annals of Palliative Medicine},
year = {2023},
doi = {10.21037/apm-23-463}
}
EUVIMED